Our Strategy

The Osteosarcoma Institute has prioritized three areas for investment:

Immediate Clinical Impact

Identify effective new drugs and drug combinations by funding clinical trials in recurrent and metastatic osteosarcoma.

  • Typically Phase II, signal-finding trials designed to get quick answers to important questions and learn from both successes and failures. To that end, we will also consider providing support for correlative studies in existing trials.
  • We envision that the first such trial will be developed through
    1) discussions with leading sarcoma physicians and treatment centers and
    2) responses to a Request for Proposal (RFP) to be issued in the summer of 2018.
  • Our goal is to open to accrual no later than March 2019.

Fill Gaps in Scientific Understanding

Gain insight by identifying and funding pre-clinical studies of translationally-relevant unknowns that are impeding progress.

  • Typically one-year grants with a renewal option. We anticipate that the initial project will result from a planned summer–2018 RFP for a project involving metastasis in osteosarcoma.

Gain insight by identifying and funding pre-clinical studies of translationally-relevant unknowns that are impeding progress.

  • Typically one-year grants with a renewal option. We anticipate that the initial project will result from a planned summer–2018 RFP for a project involving metastasis in osteosarcoma.

Osteosarcoma Outreach

Raise awareness of osteosarcoma in important communities

  • Patients and families – establish a clearinghouse of clinical and research resources
  • Drug developers and regulators – Encourage investment in research and development of new osteosarcoma therapies
  • Build the case for pharma and biotech industry investment in osteosarcoma as a viable path to approval for new agents
  • Engage the FDA to provide clear approval criteria for new drugs and drug combinations

The OSI is committed to transparency in its investment processes, and to rapid reporting of results.